Metrics as of 10/17/2026, 05:06 AM (Berlin time), refresh in progress.
Coya Therapeutics Stock
Coya Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Arun Swaminathan
- Employees
- 8
- Market cap
- $100 M
- IPO
- 29/12/2022
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and…
Coya Therapeutics stock: price history
1D
-2.1%
1W
-14.1%
1M
-4.7%
6M
-11.1%
YTD
-26.7%
1Y
-32.5%
2Y
-46.8%
5Y
–
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~14% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Coya Therapeutics
Analyst assessment of Coya Therapeutics
PRICE TARGET LOW
US$12.00
CONSENSUS
US$12.00
MEDIAN
US$12.00
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 15/09/2026
Coya Therapeutics stock metrics
P/E
-3.97
P/B
2.3
EV/EBITDA
-2.56
RETURN ON EQUITY
-15.3%
NET MARGIN
-2,723.4%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
85.3%
FLOAT SHARES
20,011,775
AVG. DAILY VOLUME (30D)
150,889
Institutional holders
Comparable stocks
Frequently asked questions about Coya Therapeutics stock
What does Coya Therapeutics do?
Coya Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Arun Swaminathan, the company employs around 8 people.
The IPO was on 29/12/2022; the stock trades on NASDAQ under the ticker COYA.
What do analysts say about Coya Therapeutics stock?
6 analysts rate the stock, the consensus is Buy (as of 15/09/2026).
The average price target is US$12.00, ranging from US$12.00 to US$12.00, with a median of US$12.00.
This is an external assessment, not a statement by Market Jury.
When does Coya Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -14% stronger than usual.
Does Coya Therapeutics pay a dividend?
No, Coya Therapeutics currently does not pay a dividend.
Which stocks are comparable to Coya Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Coya Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Coya Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.